Scheunemann, Anne; Elsner, Katrin; Germerott, Tanja et al.
Identification of Potential Distinguishing Markers for the Use of Cannabis-Based Medicines or Street Cannabis in Serum SamplesMETABOLITES. Bd. 11. H. 5. 2021
Heestermans, Marco; Naudin, Clement; Mailer, Reiner K. et al.
Identification of the factor XII contact activation site enables sensitive coagulation diagnosticsNATURE COMMUNICATIONS. Bd. 12. H. 1. 2021
Buch, Jeta; Patil, Anant; Kroumpouzos, George et al.
Idiopathic guttate hypomelanosis: Presentation and ManagementJOURNAL OF COSMETIC AND LASER THERAPY. Bd. 23. H. 1-2. 2021 S. 8-15
Regen, Tommy; Isaac, Sandrine; Amorim, Ana et al.
IL-17 controls central nervous system autoimmunity through the intestinal microbiomeSCIENCE IMMUNOLOGY. Bd. 6. H. 56. 2021
Schmeling, Andreas; Kreitner, Karl-Friedrich; Heindel, Walter et al.
Imaging for Forensic Age Diagnostics in Adolescents and Young AdultsINFORMATIONEN AUS ORTHODONTIE UND KIEFERORTHOPAEDIE. Bd. 53. H. 03. 2021 S. 199-208
Eltokhi, Ahmed; Gonzalez-Lozano, Miguel A.; Oettl, Lars-Lennart et al.
Imbalanced post- and extrasynaptic SHANK2A functions during development affect social behavior in SHANK2-mediated neuropsychiatric disordersMOLECULAR PSYCHIATRY. Bd. 26. H. 11. 2021 S. 6482-6504
Eltokhi, Ahmed; Gonzalez-Lozano, Miguel A.; Oettl, Lars-Lennart et al.
Imbalanced post- and extrasynaptic SHANK2A functions during development affect social behavior in SHANK2-mediated neuropsychiatric disorders (May, 10.1038/s41380-021-01140-y, 2021)MOLECULAR PSYCHIATRY. Bd. 26. H. 11. 2021 S. 6505-6505
Ducreux, Michel; Zhu, Andrew X.; Cheng, Ann-Lii et al.
IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor).JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021
Zhu, Andrew X.; Finn, Richard; Ducreux, Michel et al.
IMbrave150: EXPLORATORY EFFICACY AND SAFETY OF ATEZOLIZUMAB (ATEZO) plus BEVACIZUMAB (BEV) VS SORAFENIB (SOR) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WITH NON-VIRAL ETIOLOGY IN A GLOBAL PHASE III STUDYHEPATOLOGY. Bd. 74. 2021 S. 646A-647A
Breder, Valeriy Vladimirovich; Vogel, Arndt; Merle, Philippe et al.
IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in a global Ph III study.JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021